Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

NCT04648254 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Advanced Cancer
Metastatic Cancer

Interventions

DRUG: Q702

Sponsor

Qurient Co., Ltd.